A statement like tesamorelin reduces visceral fat over weeks is supported by human RCT data
(2025) NHS [accessed 29 January 2026] About lansoprazole
How do the potential benefits of GLP-1 agonists in reducing risks of heart and kidney disease compare with the risks of side effects like hypoglycemia or gallbladder disorders, and how should a clinician balance these considerations
adults are overweight or obese, only four percent of these people are prescribed GLP-1 weight-loss medicines due to concerns about safety or effectiveness, lack of healthcare provider training in weight management, excessive costs due to insurance companies refusing coverage and a toxic stigma that portrays obesity as a lack of willpower
Many people report stopping drinking or smoking without even trying
For decades, the human digestive tract had been considered little more than a hollow tube: Food went in and, er, garbage came out